Bioray Biotech Past Earnings Performance
Past criteria checks 0/6
Bioray Biotech's earnings have been declining at an average annual rate of -68.8%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 0.2% per year.
Key information
-68.8%
Earnings growth rate
-70.0%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 0.2% |
| Return on equity | -2.7% |
| Net Margin | -6.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Bioray Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 192 | -12 | 53 | 44 |
| 30 Sep 23 | 194 | -9 | 52 | 42 |
| 30 Jun 23 | 196 | -6 | 52 | 40 |
| 31 Mar 23 | 193 | -3 | 50 | 36 |
| 31 Dec 22 | 191 | 1 | 49 | 32 |
| 30 Sep 22 | 182 | 0 | 50 | 29 |
| 30 Jun 22 | 174 | 0 | 52 | 25 |
| 31 Mar 22 | 161 | -3 | 53 | 24 |
| 31 Dec 21 | 148 | -7 | 54 | 22 |
| 30 Sep 21 | 141 | -9 | 53 | 20 |
| 30 Jun 21 | 133 | -11 | 53 | 17 |
| 31 Mar 21 | 145 | -6 | 53 | 16 |
| 31 Dec 20 | 156 | 0 | 54 | 14 |
| 30 Sep 20 | 169 | 7 | 55 | 13 |
| 30 Jun 20 | 183 | 14 | 56 | 12 |
| 31 Mar 20 | 182 | 17 | 59 | 12 |
| 31 Dec 19 | 182 | 19 | 62 | 12 |
| 30 Sep 19 | 189 | 25 | 69 | 16 |
| 30 Jun 19 | 197 | 31 | 75 | 20 |
| 31 Mar 19 | 191 | 26 | 75 | 17 |
| 31 Dec 18 | 185 | 22 | 76 | 13 |
| 31 Dec 17 | 124 | 3 | 56 | 10 |
| 31 Dec 16 | 108 | 15 | 37 | 7 |
Quality Earnings: 7561 is currently unprofitable.
Growing Profit Margin: 7561 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7561 is unprofitable, and losses have increased over the past 5 years at a rate of 68.8% per year.
Accelerating Growth: Unable to compare 7561's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7561 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: 7561 has a negative Return on Equity (-2.66%), as it is currently unprofitable.